source
- Argenx to acquire macrocycle biotech Unnatural Products in up to $1.15 billion dealArgenx announced Monday it will acquire Unnatural Products, a biotech focused on macrocycle therapeutics that began as a garage startup. The transaction is structured as an up-to-$1.15 billion dea…
- Vir Biotechnology reports positive results for hepatitis D combo in first pivotal trialVir Biotechnology announced that its chronic hepatitis D treatment met its primary goal in the first of three late‑stage studies. The trial evaluated a once‑monthly combination therapy that include…